A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

BACKGROUND: Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. This study investigated the efficacy and safety of sarilumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Wolfgang A., Dasgupta, Bhaskar, Sloane, Jennifer, Giannelou, Angeliki, Xu, Yuqing, Unizony, Sebastian H., Mackie, Sarah L., Gonzalez-Gay, Miguel A., Spiera, Robert, Warrington, Kenneth J., Villiger, Peter M., Nivens, Michael C., Akinlade, Bolanle, Lin, Yong, Buttgereit, Frank, Stone, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577982/
https://www.ncbi.nlm.nih.gov/pubmed/37840134
http://dx.doi.org/10.1186/s13075-023-03177-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577982/
https://www.ncbi.nlm.nih.gov/pubmed/37840134
http://dx.doi.org/10.1186/s13075-023-03177-6

Ejemplares similares